Posted On: 01/13/2015 1:16:28 PM
Post# of 7775
People are in panic mode but they havn't read their DD about this new CEO people need to see this, its pulled from phytosciences.com if you could copy paste those 2 paragraphs into Ihub that would be great its a good understanding of our new CEO. No need to panic.... PHKK Iglow and Apostle their going to have a field day I need to get back on those boards lol
"Dr. Jones currently manages an off-grid, organic aquaponic fish, cannabis and whole plant production/cultivation in a very inhospitable desert climate in California. This system is focused on industrial hemp (IH) production of less than 0.3% Delta-9 THC/high CBD content. Per chromatograph analyses, our proprietary IH genetics of CBD:THC ratios range from 10:1 to 28:1 with THCA content of less than 0.3%, and “none detectable” on Delta-9 THC content. These strains are used for disease-specific clinical trials in conjunction with several universities throughout the United States. This company develops a complete, vertically integrated package of patentable genetics, cultivation techniques, extraction techniques, and delivery systems by range of wellness and category of human and animal disease.
As Director of Clinical Research for Phytosciences, Dr. Jones will lead a team consisting of formulation chemists, clinical trial research coordinators, cannabis product development specialists, and cannabis extraction analysts for the manufacturing and development of cannabis-based therapeutics. Dr. Jones collaborates with Dr. Akhilesh Kumar (Director of R & D) to coordinate cannabis product development to bring products to market."
"Dr. Jones currently manages an off-grid, organic aquaponic fish, cannabis and whole plant production/cultivation in a very inhospitable desert climate in California. This system is focused on industrial hemp (IH) production of less than 0.3% Delta-9 THC/high CBD content. Per chromatograph analyses, our proprietary IH genetics of CBD:THC ratios range from 10:1 to 28:1 with THCA content of less than 0.3%, and “none detectable” on Delta-9 THC content. These strains are used for disease-specific clinical trials in conjunction with several universities throughout the United States. This company develops a complete, vertically integrated package of patentable genetics, cultivation techniques, extraction techniques, and delivery systems by range of wellness and category of human and animal disease.
As Director of Clinical Research for Phytosciences, Dr. Jones will lead a team consisting of formulation chemists, clinical trial research coordinators, cannabis product development specialists, and cannabis extraction analysts for the manufacturing and development of cannabis-based therapeutics. Dr. Jones collaborates with Dr. Akhilesh Kumar (Director of R & D) to coordinate cannabis product development to bring products to market."
(0)
(0)Scroll down for more posts ▼
